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A B S T R A C T
Multiple Sclerosis (MS) is characterized by a combination of inflammatory and neurodegenerative processes in
the spinal cord and the brain. Natural and synthetic cannabinoids such as VCE-004.8 have been studied in
preclinical models of MS and represent promising candidates for drug development. VCE-004.8 is a multitarget
synthetic cannabidiol (CBD) derivative acting as a dual Peroxisome proliferator-activated receptor-gamma/
Cannabinoid receptor type 2 (PPARγ/CB2) ligand agonist that also activates the Hypoxia-inducible factor (HIF)
pathway. EHP-101 is an oral lipidic formulation of VCE-004.8 that has shown efficacy in several preclinical
models of autoimmune, inflammatory, fibrotic, and neurodegenerative diseases. EHP-101 alleviated clinical
symptomatology in EAE and transcriptomic analysis demonstrated that EHP-101 prevented the expression of
many inflammatory genes closely associated with MS pathophysiology in the spinal cord. EHP-101 normalized
the expression of several genes associated with oligodendrocyte function such as Teneurin 4 (Tenm4) and Gap
junction gamma-3 (Gjc3) that were downregulated in EAE. EHP-101 treatment prevented microglia activation
and demyelination in both the spinal cord and the brain. Moreover, EAE was associated with a loss in the
expression of Oligodendrocyte transcription factor 2 (Olig2) in the corpus callosum, a marker for oligoden-
drocyte differentiation, which was restored by EHP-101 treatment. In addition, EHP-101 enhanced the ex-
pression of glutathione S-transferase pi (GSTpi), a marker for mature oligodendrocytes in the brain. We also
found that a diet containing 0.2% cuprizone for six weeks induced a clear loss of myelin in the brain measured by
Cryomyelin staining and Myelin basic protein (MBP) expression. Moreover, EHP-101 also prevented cuprizone-
induced microglial activation, astrogliosis and reduced axonal damage. Our results provide evidence that EHP-
101 showed potent anti-inflammatory activity, prevented demyelination, and enhanced remyelination.
Therefore, EHP-101 represents a promising drug candidate for the potential treatment of different forms of MS.
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Multiple sclerosis (MS) is an autoimmune disease that affects the
central nervous system (CNS) and is characterized by pathological
changes, including neuroinflammation, demyelination and axon injury
(Kipp et al., 2009; Lassmann, 2010; Scolding and Franklin, 1998). The
spontaneous repair of damaged myelin sheaths and axons has been
described during the remission period of classical relapsing-remitting
MS (RRMS), where demyelinated axons could be rewrapped by the
regenerated myelin sheath, thus ameliorating axonal dysfunction. In
this sense, the remission period is also considered the period of re-
myelination (Fox et al., 2015; Kister et al., 2013), which is important
because it could be a key time for the treatment of RRMS patients with
drugs preventing inflammation and enhancing remyelination.
Small molecules including cannabinoids acting at druggable targets
of the endocannabinoid system (ECS) are being explored for the man-
agement of CNS pathologies including MS (Chiurchiu et al., 2018). In
this sense, several lines of evidence suggested a role for the ECS in
oligodendrocyte function and remyelination activity in MS (Bernal-
Chico et al., 2015; Feliu et al., 2017; Ilyasov et al., 2018). The ECS is
composed by the G-protein coupled receptors Cannabinoid type 1 (CB1)
and type 2 (CB2), endocannabinoids and the enzymes regulating their
synthesis and catabolism. In addition, cannabinoids of a different
nature also target ionotropic receptors of the Transient receptor po-
tential channels (TRP channels) family and nuclear receptors such as
peroxisome proliferator-activated receptors (PPARs) (Barrie and
Manolios, 2017; Pistis and O'Sullivan, 2017). CB1 receptors are ex-
pressed mainly in the CNS at neuronal terminals and regulate neuro-
transmitter release and psychoactive processes. In contrast, CB2 re-
ceptors are located primarily in the peripheral immune system, and its
expression is increased during neuroinflammation on activated micro-
glia in the CNS (Pacher and Mechoulam, 2011; Sanchez and Garcia-
Merino, 2012). Key considerations for developing CB2 receptor agonists
include absence of psychoactive effects, sustained anti-inflammatory
activity, tissue/cell protection, lack of cardiovascular adverse effects
and efficacy in several disease models on neuroinflammation including
MS (Kong et al., 2014; Navarrete et al., 2018; Pacher and Kunos, 2013;
Pacher and Mechoulam, 2011; Tomas-Roig et al., 2016).
PPARs are members of the nuclear hormone receptor superfamily of
ligand-activated transcriptional factors (Ricote et al., 1998a) with well-
identified regulatory roles in lipid and glucose homeostasis and adi-
pocyte differentiation (Straus and Glass, 2007). In addition to adipo-
cytes and hepatocytes, PPARγ has been shown to be expressed in dif-
ferent CNS cells and in immune cells (Bernardo and Minghetti, 2006).
Furthermore, PPARγ has been described as an important factor in the
regulation of the immune response (Daynes and Jones, 2002). In this
sense, PPARγ activation has been shown to suppress the expression of
inflammatory cytokines in astrocytes and macrophages/microglia
(Ricote et al., 1998b; Storer et al., 2005; Xu et al., 2007). Furthermore,
PPARγ stimulated oligodendrocyte differentiation from neural stem
cells (Kanakasabai et al., 2012), promoted and accelerated the differ-
entiation of oligodendrocyte progenitor cells in vitro with an additional
increase in antioxidant defences (Bernardo et al., 2009; De Nuccio
et al., 2011) and increased lipid production and terminal differentiation
of cultured oligodendrocytes (Roth et al., 2003), thus suggesting an
additional possible protective role of PPARγ in MS as a mediator of
remyelination. The neuroprotective effects of PPARs, including PPARγ,
have also been widely documented in vitro in various experimental
paradigms of neurodegeneration, broadening its potential therapeutic
perspectives in MS (Brodbeck et al., 2008; Inestrosa et al., 2005; Luna-
Medina et al., 2005; Zhao et al., 2006).
We have previously shown that VCE-004.8 is a promising cannabi-
diol (CBD) derivative acting as a dual agonist of PPARγ and CB2 that
also activates the HIF pathway (Navarrete et al., 2018). Indeed, VCE-
004.8 prevented neuroinflammation and demyelination in two different
murine models of MS, namely EAE and Theiler's virus-induced
demyelinating disease (Navarrete et al., 2018). EHP-101 is an oral
formulation of VCE-004.8 that also showed efficacy in a murine model
of systemic sclerosis (SSc) (Garcia-Martin et al., 2019; Garcia-Martin
et al., 2018). EHP-101 has completed a Phase I clinical study (clin-
icaltrial.gov: NCT03745001) and initiation of Phase II studies in SSc
and MS patients are being planned.
Although most current therapies for MS are directed towards
modulation of the exacerbated immune response (McFarland and
Martin, 2007), novel therapies aimed at axonal remyelination are ur-
gently needed. Herein we show the efficacy of EHP-101 in preventing
neuroinflammation and demyelination in EAE and enhancing re-
myelination in the cuprizone model of demyelination.
2. Material and methods
2.1. Compounds
For preparing EHP-101, VCE-004.8 [(1′R,6′R)-3-(Benzylamine)-6-
hydroxy-3′-methyl-4-pentyl-6′-(prop-1-en-2-yl) [1,1'bi(cyclohexane)]-
2′,3,6-triene-2,5-dione)] was dissolved in Corn oil and Maisine® CC
(1:1) (Garcia-Martin et al., 2018). The chromatographic purity of VCE-
004.8 in EHP-101 was 97.6%.
2.2. Animals
All experiments were performed in strict accordance with European
Union (EU) and governmental regulations. Handling of animals was
performed in compliance with the guidelines of animal care set by the
EU guidelines 86/609/EEC, and the Ethics Committees on Animal
Experimentation at the Cajal Institute (CSIC, Madrid) and the
University of Córdoba (UCO, Córdoba, Spain) approved all the proce-
dures described in this study (for EAE at Cajal Institute protocol
number: 96 2013/03 CEEA-IC and for cuprizone model at UCO protocol
number: 2018PI/02 (UCO). Measures to improve welfare assistance and
clinical status as well as endpoint criteria were established to minimize
suffering and ensure animal welfare. Briefly, wet food pellets are placed
on the bed-cage when the animals begin to develop clinical signs to
facilitate access to food and hydration. For the EAE model, female
C57BL/6 mice were purchased from Harlan (Barcelona, Spain) and for
the cuprizone model, male C56BL/6 mice were purchased from Janvier
Labs (Le Genest-Saint-Isle, France). All animals were housed in the
animal facilities under the following controlled conditions: 12 h light/
dark cycle; temperature 20 °C (± 2 °C) and 40–50% relative humidity
with free access to standard food and water.
2.3. Induction and assessment of EAE
EAE was induced in C57BL/6 female mice at 6–8 weeks of age by
subcutaneous immunization with Myelin Oligodendrocyte Glycoprotein
Peptide Fragment 35–55 (MOG35–55) (300 μg: peptide synthesis sec-
tion, CBM, CSIC, Madrid, Spain) and 200 μg of Mycobacterium tu-
berculosis (H37Ra Difco, Franklin Lakes, NJ, USA) in a 1∶1 mix with
incomplete Freund's adjuvant (CFA, Sigma). On the same day and
2 days later, mice were injected intraperitoneally with 200 ng of per-
tussis toxin (Sigma) in 0.1 ml Phosphate buffer saline (PBS). Control
animals (CFA) were inoculated with the same emulsion without MOG
and they did not receive pertussis toxin. Treatment started at day 8
post-immunization when animals showed the first symptoms of the
disease and consisted of daily oral EHP-101 administration (1, 5, 10 and
20 mg/kg) for the following 21 days. The mice were examined daily for
clinical signs of EAE and disease scores were measured as follows: 0, no
disease; 1, limb tail; 2, limb tail and hind limb weakness; 3, hind limb
paralysis; 4, hind limb and front limb paralysis; 5, moribund and death.
All animals were sacrificed at 28 days for further analysis.
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2.4. Cuprizone-induced demyelination
To induce demyelination, 8-week old C57BL/6 male mice were fed
with 0.2% cuprizone (CPZ) TD.140800 diet (Envigo, Barcelona, Spain)
for six weeks. Control group (no demyelination) was fed with control
mouse TD.00217 diet (Envigo, Barcelona, Spain) for the entire period.
To study the effect on remyelination, EHP-101 was administered once
daily by oral gavage at 20 mg/kg from week six. For comparison, ani-
mals in the CPZ control group (maximal demyelination) received the
same volume of vehicle by gavage. To study the dynamic effect of EHP-
101 on remyelination, animals in each group were sacrificed at weeks
6, 7 (6 + 1 W), 8 (6 + 2 W) for further analysis.
2.5. Tissue processing
Mice were anesthetized by i.p. administration of a ketamine-xyla-
zine or pentobarbital solution and they were transcardially perfused
with saline 0.9%. The spinal cord was obtained by extrusion with
saline. Brain and cervical spinal cord were immediately frozen and kept
at −80 °C for RT-PCR analysis. The remaining brain and spinal cord
were fixed in 4% paraformaldehyde in 0.1 M PBS, washed in 0.1 M PBS,
cryoprotected with a 15% and then a 30% solution of sucrose in 0.1 M
PBS, and frozen at −80 °C. Free-floating brain (sections were taken
between bregma 0.38 and 0.98 mm) and thoracic spinal cord sections
(50 μm thick: Leica Microsystems CM1900 cryostat, Barcelona, Spain)
were then processed for immunohistochemistry or immuno-
fluorescence. In the case of cuprizone model whole brains were fixed,
cryoprotected and frozen at −80 °C for further analysis.
2.6. Inflammatory infiltrate analysis
Spinal cord slices were stained with hematoxylin-eosin (H&E) to
analyze the infiltrates in the parenchyma. Inflammatory infiltrates were
evaluated on a scale of 0 to 4, the score reflecting the number of in-
filtrates in the thoracic spinal cord sections. A score of 4 reflects the
largest number of infiltrates with all the intermediate scores (1, 2, and
3) defining the increase in the density of infiltrates in the spinal cord
tissue.
2.7. Immunohistochemical analysis
For IHC analysis, free-floating thoracic spinal cord (50 μm) sections
were washed with 0.1 M Phosphate buffer (PB). Endogenous peroxidase
activity was inhibited with 3.3% hydrogen peroxide in methanol. The
sections were blocked with 2.5% normal horse serum and then in-
cubated overnight at 4 °C in blocking buffer with a rabbit anti-Teneurin
4 antibody (1:50: Novus Biological, Colorado, USA) or anti-CD3 anti-
body (1:50: Santa Cruz Biotechnology, Santa Cruz, CA, USA). Slides
were incubated with ImmPRESS reagent (Vector Laboratories;
Burlingame, Ca, USA) and then developed with diaminobenzidine
chromogen (Merck, Darmstadt, Germany). Samples were photo-
graphed, digitalized using a Leica DFC420c camera and analyzed using
Image J software. Myelin integrity was analyzed using the Hito
CryoMyelinStain™ Kit (Gold phosphate complex Myelin Staining Kit)
following manufacturer's recommendation (Hitobiotech Corp.,
Kingsport, TN, USA).
2.8. Confocal microscopy analysis
For antigen retrieval, spinal cord or brain sections were boiled for
10 min in sodium citrate buffer (10 mM, pH 6.0) or Tris-EDTA buffer
(10 mM Tris Base, 1 mM EDTA, 0.05% Tween 20, pH 9.0) (Sigma-
Aldrich, St. Louis, MO, USA). The sections were washed three times in
PBS. Nonspecific antibody-binding sites were blocked for 1 h at room
temperature with 3% bovine serum albumin (BSA) (Sigma-Aldrich, St.
Louis, MO, USA in PBS). Next, the sections were incubated overnight at
4 °C with the following primary antibodies diluted in PBS with 3% BSA:
microglia cells were stained with a rabbit anti-ionized calcium binding
adaptor molecule 1 (Iba-1) antibody (1∶1,000; Wako Chemical Pure
Industry, Osaka, Japan), astrocytes were stained with a mouse anti-glial
fibrillary acidic protein (GFAP) antibody (1:500, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), myelin basic protein was marked
with a rabbit anti-Myelin Basic Protein (MBP) antibody (1:1000;
Abcam, Cambridge, UK), oligodendrocytes were marked with a mouse
anti-Olig2 (1:100, Santa Cruz, CA, USA) and a rabbit anti-GSTPi (1:250,
Abcam, Cambridge, UK) axonal damage was determined with a mouse
anti-Neurofilament H (NF-H) Nonphosphorylated antibody (SMI-32)
(1:50; Biolegend, CA, USA). After extensive washing in PBS, slides were
incubated with secondary antibodies for 1 h at room temperature in the
dark. The immunoreactions were revealed using anti-rabbit Texas Red
(1:100), anti-mouse/rabbit Alexa 488 (1:100) obtained from Thermo
Fischer Scientific, Walthamm, MA, USA. The slides were then mounted
using Vectashield Antifade Mounting Medium with DAPI (Vector
Laboratories, Burlingame, Ca, USA). All images were acquired using a
spectral confocal laser-scanning microscope LSM710, (Zeiss, Jena,
Germany) with a 20×/0.8 Plan-Apochromat lens and quantified in
9–15 randomly chosen fields using ImageJ software (http://rsbweb.nih.
gov/ij/).
2.9. RNA-Seq and bioinformatic analysis
Total RNA was isolated from spinal cord tissue using QIAzol lysis
reagent (Qiagen, Hilden, Germany) and purified with RNeasy Lipid
Tissue Mini kit (Qiagen). Then, samples were processed for high
throughput sequencing using poly-A selection with the TruSeq Stranded
mRNA Library Prep Kit (Cat. No. RS-122-2101, Illumina, San Diego, CA,
USA). In brief, 1μg of total RNA from each sample was used to construct
a cDNA library, followed by sequencing on the Illumina HiSeq 2500
system with single end 50 bp reads and ~ 40 millions of reads per
sample (n = 3 per group). FASTQ files were pre-processed with
Trimmomatic (v0.36) (Bolger et al., 2014) and aligned to mouse
genome assembly mm10 using HISAT2 (v2.1.0) (Kim et al., 2015).
Then, counts per gene matrix were obtained with featureCounts
(v1.6.1) (Liao et al., 2014) using the in-built RefSeq annotation for
mm10 genome assembly and the differential expression analysis was
carried out using DESeq2 (v1.20.0) (Love et al., 2014), excluding genes
with less than 15 counts across all samples. The functional over-re-
presentation analyses were performed using EnrichR (Kuleshov et al.,
2016) and clusterProfiler (Yu et al., 2012). All the P values were ad-
justed to control the false discovery rate (FDR) using the Benjamini and
Hochberg approach (Klipper-Aurbach et al., 1995). RNA-seq data have
been deposited in the Gene Expression Omnibus databank (accession
no. GSE131854).
2.10. Quantitative reverse transcriptase-PCR
Total RNA (1 μg) was retrotranscribed using the iScript cDNA
Synthesis Kit (Bio-Rad, Hercules, CA, USA) and the cDNA analyzed by
real-time PCR using the iQTM SYBR Green Supermix (Bio-Rad) and a
CFX96 Real-time PCR Detection System (Bio-Rad). Glyceraldehyde-3-
Phosphate Dehydrogenase (GAPDH) gene was used to standardize
mRNA expression in each sample. Gene expression was quantified using
the 2-ΔΔCt method and the percentage of relative expression against
controls was represented. The primers used in this study are described
in Table A.1.
2.11. Data analysis
All the in vivo data are expressed as the mean ± SEM. One-way
analysis of variance (ANOVA) followed by the Tukey's post-hoc test for
parametric analysis or Kruskal-Wallis post-hoc test in the case of non-
parametric analysis tests were used to determine the statistical
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significance. The level of significance was set at p˂0.05. Statistical
analyses were performed using GraphPad Prism version 8.00
(GraphPad, San Diego, CA, USA).
3. Results
3.1. EHP-101 attenuates clinical severity and neuroinflammation in EAE
The efficacy of EHP-101 in MS was first evaluated in EAE, per-
forming the treatments at an early stage of the disease since mice re-
ceived increasing doses of EHP-101 at day 8 post-immunization (p.i.).
Subcutaneous immunization with MOG35–55 induced EAE in all mice
that received the vehicle alone. All vehicle-treated mice developed a
disease that peaked by day 16 p.i. and maintained at day 28 p.i. By
contrast, the reduced clinical score showed therapeutic efficacy of EHP-
101 with all the dose levels tested, with the highest dose (20 mg/kg)
able to prevent the symptoms completely (Fig. 1A p = .0002
EAE + EHP-101 20 mg/kg vs EAE + Vehicle; p = .0046 EAE + EHP-
101 10 mg/kg vs EAE + Vehicle; p = .0068 EAE + EHP-101 5 mg/kg
vs EAE+ Vehicle). Clinical score data from Fig. 1 used to determine the
area under curve as shown in Fig. 1B (p< 0.0001 EAE+ EHP-101 1/5/
10/20 mg/kg vs EAE + Vehicle) clearly demonstrated that EHP-101
improved symptomatology in a dose-dependent manner.
To determine whether EHP-101 was able to target neuroin-
flammation in EAE, immune cell infiltration, microgliosis and astro-
gliosis were evaluated in the spinal cord. Histopathological analysis
showed that infiltration of immune cells into the spinal cord was re-
duced by EHP-101 treatment as shown by hematoxylin-eosin staining
(Fig. 2A, B p< 0.0001 EAE + Vehicle vs CFA; p = .0015 EAE + EHP-
101 20 mg/kg vs EAE + Vehicle). In addition, EHP-101 treatment re-
duced the number of CD3+ T cells in the spinal cord of EAE mice
(Fig. 2A, C p<0.0001 EAE + Vehicle vs CFA; p = .0456 EAE + EHP-
101 20 mg/kg vs EAE + Vehicle). Moreover the extensive microglia/
macrophage activation (Fig. 2A, D p = .0003 EAE + Vehicle vs CFA;
p = .0006 EAE + EHP-101 20 mg/kg vs EAE + Vehicle) and astrocyte
activation (Fig. 2A, E p< 0.0001 EAE + Vehicle vs CFA; p = .0051
EAE + EHP-101 20 mg/kg vs EAE + Vehicle) in the spinal cord of EAE
mice evidenced by both Iba-1 and GFAP staining was greatly reduced
by EHP-101.
MS pathology is characterized by focal demyelinating lesions in the
CNS at both spinal cord and brain levels. Therefore, to determine the
extent of demyelination, myelin was evaluated by MBP immunolabel-
ling. A clear demyelination was found in the spinal cord of EAE mice
that was significantly prevented by EHP-101 treatment (Fig. 2A, F
p = .0001 EAE + Vehicle vs CFA; p< 0.0001 EAE + EHP-101 vs
EAE + Vehicle).
Cerebral cortical demyelination as well as callosal pathology are
widely recognized features of MS (Kornek and Lassmann, 2003;
Rasmussen et al., 2007; Storch et al., 2006). In addition, the cerebral
cortex plays a central role in interhemispheric communication, and
callosal atrophy in MS patients has been shown to correlate with dis-
ability status (Bonzano et al., 2008; Manson et al., 2006; Manson et al.,
2008). Therefore, we also examined whether these structures might
also be affected in EAE mice. An increase in inflammatory lesions was
seen throughout the EAE forebrain (Fig. 3A). Specifically, we observed
that microglial reactivity was increased in corpus callosum of EAE mice
and the treatment with EHP-101 reverted the microgliosis process
(Fig. 3B p = .0002 EAE + Vehicle vs CFA; p = .0395 EAE + EHP-101
20 mg/kg vs EAE + Vehicle). Furthermore, brain sections from EAE-
affected mice were also analyzed for the distribution of MBP reactivity.
MBP immunoreactivity appeared significantly reduced in cerebral
cortex (Fig. 3C p = .0159 EAE + Vehicle vs CFA; p = .0024
EAE + EHP-101 20 mg/kg vs EAE + Vehicle) and this loss of myelin
expression was strongly reverted by EHP-101 treatment. Moreover, EAE
is associated with a loss in the expression of Olig2 in the corpus cal-
losum, a marker for the onset of oligodendrocyte differentiation, which
was restored by EHP-101 treatment (Fig. 3D p<0.0001 EAE + Vehicle
vs CFA; p = .0008 EAE + EHP-101 20 mg/kg vs EAE + Vehicle). In
addition, EHP-101 enhanced the expression of glutathione S-transferase
pi (GSTpi), a cytosolic isoenzyme used as a marker for mature oligo-
dendrocytes in the brain (Fig. 3E p = .0222 EAE + EHP-101 20 mg vs
EAE + Vehicle). These data are indicative of the potential of EHP-101
to prevent demyelination in an MS murine model.
3.2. EHP-101 normalizes EAE transcriptomic signature in the spinal cord
To evaluate the global expression changes produced by EHP-101
treatment, we performed an RNA-Seq analysis of the spinal cords from
mice in the following conditions: Control, EAE and EAE with EHP-101
treatment (20 mg/kg). Sequencing data for three biological replicates
were obtained for each experimental group. Then, we compared the
transcriptomic profile between the different conditions to get a first
insight into the changes occurring in the model, with or without
treatment. As expected, we found many changes, both in magnitude
and significance in EAE mice compared to the group treated with EHP-
101 (Fig. 4A). Then, to evaluate those changes at a biological level, we
performed an over-representation analysis using genes that surpassed
the cutoff of an adjusted P < .05 and absolute fold change>2 in the
EAE vs control and EAE + EHP-101 vs EAE comparisons. The more
significant enrichments were found in the groups of upregulated genes
by EAE and downregulated genes by the treatment. We observed a
complementary signature between those two groups, where gene on-
tology terms like “regulation of immune response”, “inflammatory re-
sponse” or “cytokine-mediated signaling pathway” appeared, high-
lighting an anti-inflammatory effect of the EHP-101 treatment on the
spinal cord. Interestingly, among those genes participating in the in-
flammatory response, we also found enriched terms related with the
Fig. 1. EHP-101 attenuates clinical severity and neuropathology in EAE model.
(A) EHP-101 significantly ameliorated the clinical signs and progression of EAE.
Results are expressed as mean ± SEM (n = 6 animals per group). **p < .01,
***p < .001 EAE + EHP-101 vs EAE + Vehicle (one-way ANOVA followed by
the Tukey's post-hoc test). (B) Clinical activity was quantified by measuring the
area under curve. Results are expressed as mean ± SEM (n = 6 animals per
group). ***p < .001 EAE + EHP-101 vs EAE + Vehicle (one-way ANOVA
followed by the Tukey's post-hoc test).
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cellular response to oxidative stress as “cellular response to oxygen-
containing compound”, “positive regulation of reactive oxygen species
biosynthetic process” or “positive regulation of superoxide anion gen-
eration” (Fig. 4B). The heatmap in Fig. 4C represents genes from the
“cytokine-mediated signaling pathway” that are induced by EAE and
downregulated by EHP-101. Furthermore, to confirm this anti-in-
flammatory effect of EHP-101 in the spinal cord we determined the
gene expression by RT-PCR of several genes such as Interleukin 6 (IL-6),
Tissue inhibitor matrix metalloproteinase 1 (Timp1), vascular cell ad-
hesion molecule 1 (Vcam), Interleukin 1 beta (IL-1β), CeC Motif
Fig. 2. EHP-101 significantly reduces glial reactivity and preserves myelin structure in the spinal cord of EAE animals. (A) Cross-sectional images of thoracic spinal
cord of 50 μm thick, in which hematoxylin-eosin staining, immunohistochemistry with anti-CD3 and immunofluorescence with anti-Iba1, GFAP and myelin staining
MBP were studied in the white matter (dashed line separates gray and white matter). Scale bars equivalent to 100 μm. The quantifications of each marker (BeF) are
shown as mean ± SEM (n = 5 animals per group), and significance was determined by one-way ANOVA followed by the Tukey's or Kruskall-Wallis post-hoc tests.
***p < .001 EAE + Vehicle vs CFA; #p < .05, ##p < .01, ###p < .001 EAE + EHP-101 vs EAE + Vehicle.
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Chemokine Ligand 4 (Ccl4) and CeC Motif Chemokine Ligand 2 (Ccl2).
We show in Fig. 4D that EHP-101 treatment downregulated the ex-
pression of these genes upregulated in EAE mice (Il6: p = .0360
EAE + Vehicle vs CFA; p = .0451 EAE + EHP-101 20 mg/kg vs
EAE + Vehicle; Timp1: p = <0.0001 EAE + Vehicle vs CFA;
p = .0001 EAE + EHP-101 20 mg/kg vs EAE + Vehicle; VCAM:
p = .0058 EAE + Vehicle vs CFA, p = .0381 EAE + EHP-101 20 mg/
kg vs EAE + Vehicle; IL1b: p = .0018 EAE + Vehicle vs CFA;
p = .0027 EAE + EHP-101 20 mg/kg vs EAE + Vehicle; Ccl4:
p = <0.0001 EAE + Vehicle vs CFA; p = <0.0001 EAE + EHP-101
20 mg/kg vs EAE + Vehicle; Ccl2: p = .0003 EAE + Vehicle vs CFA;
p = .0054 EAE + EHP-101 vs EAE + Vehicle), thus validating the
results found in the RNA-Seq analysis.
Next, we performed a second analysis to explore changes in the
opposite direction to the pattern shown by the pro-inflammatory genes.
Thus, we selected down-regulated genes in the EAE vs control com-
parison and up-regulated in EAE + EHP-101 vs EAE comparison. We
intersected both groups of genes to evaluate the overlap between them,
resulting in a total of 193 genes downregulated in the untreated model
that increased their expression in response to the treatment (Fig. 5A).
Then we performed a second functional analysis, using the list of
overlapping genes as input, to explore the most significantly enriched
Gene Ontology (GO) terms. As depicted in Fig. 5B, we found several
terms related to the metabolic process of sterols and hydroxy com-
pounds at the top of the list. However, given the background of the
disease, we decided to focus on the “myelination” process. To explore
the changes of features belonging to this annotation, we depicted the
expression levels of genes that produced this result in the heatmap
shown in Fig. 5C. This allowed us to identify several key genes of the
myelination process that were restoring their levels with EHP-101
treatment. Interestingly, these results indicated that EHP-101 normal-
ized the expression of several genes associated with oligodendrocyte
function, such as Gap junction gamma-3 (Gjc3), also called Connexin
29, and Teneurin-4 (Tenm4) that were downregulated in EAE. These
Fig. 3. Demyelination with persistent activation of microglia and loss of Olig2 expression was prevented by EHP-101 treatment. (A) Representative confocal
microscopy images of immunolabeled cells for Iba1 (marked with arrow), MBP (arrowhead in panel), Olig2 (pointed by arrows) and GSTpi expression in corpus
callosum and cortex. Scale bars equivalent to 100 μm. (B-E) The quantifications of each marker are shown as mean ± SEM (n = 5 animals per group), and
significance was determined by one-way ANOVA followed by the Tukey's post-hoc test. *p < .05, ***p < .001 EAE + Vehicle vs CFA; #p < .05, ##p < .01,
###p < .001 EAE + EHP-101 vs EAE + Vehicle.
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results are relevant since Tenm4 has been described as a critical reg-
ulator of oligodendrocyte differentiation and CNS myelination (Suzuki
et al., 2012). To validate the transcriptomic analysis, we studied the
expression of Gjc3 and Tenm4 by RT-PCR (Fig. 5D Tenm4: p = .0020
EAE + Vehicle vs CFA; p = .0032 EAE + EHP-101 20 mg/kg vs
EAE + Vehicle; Gjc3: p = .0006 EAE + Vehicle vs CFA; p = .0462
EAE + EHP-101 20 mg/kg vs EAE + Vehicle) and the protein levels by
IHC. As depicted in Fig. 5E (p = ˂ 0.0001 EAE + Vehicle vs CFA:
Fig. 4. Gene expression profiling of the effect of EHP-101 in EAE model. (A) MA plots of the EAE or EAE+ EHP-101 vs control comparisons. The X axis represents the
average expression as the mean of normalized counts while the Y axis indicates the magnitude of the change as the log2 transformed fold change. The color indicates
genes that surpassed the cutoff of adjusted P < .05 and fold change<−2 (blue) or > 2 (red). (B) Over-representation analysis results for Gene Ontology (GO)
terms related with inflammation and response to oxidative stress on genes up-regulated by EAE and down-regulated by the treatment. Dots indicate a significant over-
representation (adjusted P < .05) of a Gene Ontology term (Y axis) for a given comparison (X-axis). (C) Heatmap depicting the expression levels for selected genes
included in the “cytokine-mediated signaling pathway”. (D) The mRNA expression for inflammatory marker in spinal cord (IL-6, Timp1, VCAM, IL1b, CCL2 and
CCL4) was quantified by qPCR and normalized versus GAPDH. Data represent the mean ± SEM, and significance was determined by one-way ANOVA followed by
the Tukey's post-hoc test. *p < .05, **p < .01, ***p < .001 EAE + Vehicle vs CFA; #p < .05, ##p < .01, ###p < .001 EAE + EHP-101 vs EAE + Vehicle.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 5. EHP-101 treatment normalized the expression of genes associated with oligodendrocyte function. (A) Venn Diagram indicating the overlap between the sets of
down regulated genes at EAE vs Control comparison (Adjusted P < .1 and fold change< 0) and up regulated genes at EAE + EHP-101 vs EAE comparison (Adjusted
P < .1 and fold change>0). (B) Functional analysis results for the set of 193 overlapping genes. The scatter plot represents the significance of the enrichment for
the top 15 over-represented Gene Ontology (Biological Process) terms as the -log10 transformed adjusted P value. (C) Heatmap depicting the expression levels for
genes annotated with the “myelination” GO term included in the set of 193 overlapping features. (D) The mRNA expression for myelination-related genes (Tenm4
and Gjc3) was quantified by qPCR and normalized versus GAPDH. (E) Immunohistochemistry labelling of spinal cord for Teneurin-4 in CFA, EAE+ + Vehicle and
EAE + EHP-101 are shown. Scale bars equivalent to 200 μm. The quantification of expression of Teneurin-4 in the white and the gray matter (bottom panel). Data
represent the mean ± SEM (n = 5 animals per group) and significance were determined by one-way ANOVA followed by the Tukey's post-hoc test. **p < .01,
***p < .001 EAE + Vehicle vs CFA; #p < .05, ##p < .01, ###p < .001 EAE + EHP-101 vs EAE + Vehicle.
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p = <0.0001 EAE + EHP-101 20 mg/kg vs EAE + Vehicle), a de-
crease of Tenm4 expression was observed in white matter of spinal cord
compared to the CFA group which was prevented by EHP-101 treat-
ment. Taken together, these results are indicative of the potential of
EHP-101 to prevent demyelination in EAE model.
3.3. EHP-101 accelerates remyelination in cuprizone-challenged mice
To evaluate the effect of EHP-101 on remyelination during the acute
CPZ-induced demyelination protocol (Fig. 6A), brain coronal sections
from animals after 6 weeks of CPZ 0.2% diet and 2 weeks of EHP-101
Fig. 6. Effect of EHP-101 treatment on remyelination in acute CPZ-induced demyelination. (A) Experimental procedure (B). Histological study of myelin by
Cryomyelin staining in corpus callosum and quantification of the mean intensity is shown (D). (C) Immunodetection of MBP in the cerebral cortex, and (E) the
quantification of MBP immunoreactivity. Scale bars equivalent to 200 μm (B) 100 μm (C). Data represent the mean ± SEM (n = 5 animals per group), and
significance was determined by one-way ANOVA followed by the Tukey's post-hoc test. ***p < .001 CPZ 6 W or CPZ 6 W + 1 or CPZ 6 W + 2 vs Control;
###p < .001 CPZ 6 W +1 + EHP-101 vs CPZ 6 W +1, †††p < .001 CPZ 6 W +2 + EHP-101 vs CPZ 6 W +2.
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treatment were evaluated. In this model, EHP-101 treatment was
started after removal of the CPZ diet to study the effect of EHP-101 on
spontaneous remyelination. First, the evaluation of MBP was de-
termined by CryoMyelin and IHC staining (Fig. 6B and C, respectively).
Spontaneous recovery from demyelination was insignificant after 1 and
2 weeks in untreated mice but remyelination was significantly
accelerated by EHP-101 treatment in both the corpus callosum (Fig. 6D
p = <0.0001 CPZ6W, CPZ6 + 1 W, CPZ6 + 2 W vs Control;
p = <0.0001 CPZ6 + 1 W + EHP-101 20 mg/kg vs CPZ6 + 1 W;
p = <0.0001 CPZ6 + 2W+ EHP-101 20 mg/kg vs CPZ6 + 2 W) and
the cerebral cortex (Fig. 6E p = <0.0001 CPZ6W, CPZ6 + 1 W,
CPZ6 + 2 W vs Control; p = <0.0001 CPZ6 + 1 W + EHP-101
Fig. 7. Impact of EHP-101 treatment on microglia and astrocytes activation in acute CPZ-induced demyelination. (A) Expression of Iba1 in corpus callosum and
quantification (C). (B) Astrogliosis was determined by immunofluorescence studies of GFAP in corpus callosum and quantification of intensity is shown (D). Scale
bars equivalent to 100 μm. Data represent the mean ± SEM (n = 5 animals per group), and significance was determined by one-way ANOVA followed by the
Tukey's post-hoc test. ***p < .001 CPZ 6 W or CPZ 6 W+ 1 or CPZ 6 W+ 2 vs Control; **p˂0.01 CPZ 6 W+ 2 vs Control; ##p < .01 CPZ 6 W+1+ EHP-101 vs
CPZ 6 W +1.
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20 mg/kg vs CPZ6 + 1 W). Moreover, we investigated the effect of
EHP-101 on neuroinflammation-associated glial activation by staining
Iba-1+ and GFAP+ cells in the corpus callosum. In control mice, low
expression levels of Iba-1+ and GFAP+ cells were detected but mice
exposed to CPZ showed microglial and astrocytic activation, which was
attenuated by EHP-101 treatment (Fig. 7A and B). Quantitative as-
sessment also showed a significant increase in the number of Iba1+ and
GFAP+ cells in corpus callosum upon CPZ intoxication. Microgliosis
was ameliorated after 1 week of EHP-101 treatment and astrocytes
activation also showed a tendency for inhibition (Fig. 7C p = <0.0001
CPZ6W, CPZ6 + 1 W, CPZ6 + 2 W vs Control; p = .0017
CPZ6 + 1 W + EHP-101 20 mg/kg vs CPZ6 + 1 W; Fig. 7D
p = <0.0001 CPZ6W, CPZ6 + 1 W vs Control; p = .0017
CPZ6 + 2 W vs Control). To examine the effects of EHP-101 on cu-
prizone-induced demyelination of axons in the corpus callosum, we
investigated the non-phosphorylated form of neurofilament proteins
(SMI-32 staining). Although SMI-32 immunoreactivity is normally seen
in axons, its accumulation in axonal spheroids is a characteristic of
axonal pathology. Increased SMI-32 labeling after 6 and 7 weeks of CPZ
intoxication demonstrated that there was a significant effect on axons
and this effect was ameliorated after 1 week of EHP-101 treatment
(Fig. 8).
4. Discussion
Natural products, including phytocannabinoids, have been suc-
cessfully used for the development of synthetic and semisynthetic de-
rivatives with improved bioactivities (Appendino et al., 2010). We have
developed the compound VCE-004.8, a synthetic derivative of CBD,
which is a dual agonist for PPARγ/CB2 that also inhibits the activity of
HIF prolyl hydroxylases (PHDs) (del Rio et al., 2016; Navarrete et al.,
2018). Therefore, VCE-004.8 is targeting several pathways that may
have a positive effect on neuroinflammation and remyelination as ob-
served in EAE and Theiler's Murine Encephalomyelitis Virus-induced
demyelinating models (Navarrete et al., 2018). Herein we have studied
the effect of EHP-101, an oral lipidic formulation of VCE-004.8, in two
of the most commonly used models of demyelination, which are EAE
and toxically induced demyelination via cuprizone (Lassmann and
Bradl, 2017).
EAE in C57BL/6 mice has generally been thought to predominantly
target the spinal cord, leading to sensory and motor impairments.
Nevertheless, it is also recognized that EAE involves other CNS struc-
tures including the cerebellum and the hippocampus (Brown and
Sawchenko, 2007; MacKenzie-Graham et al., 2012). Our data clearly
indicate that EHP-101 is effective in alleviating neuroinflammation in
the spinal cord, in the cerebral cortex and in the corpus callosum. In the
EAE model we cannot distinguish whether the effect of EHP-101 occurs
in the peripheral immune system, in the CNS or both. It has been de-
monstrated that the blood-brain-barrier (BBB) can be disrupted in EAE
allowing for the migration of autoimmune cells and molecules to the
brain (Bennett et al., 2010). However, it is likely that EHP-101 may
exert anti-inflammatory effects by acting both in the peripheral immune
system and in the CNS. The formulation of VCE-004.8 in the selected
vehicle (Corn oil and Maisine CC) may indeed explain the potential
action of VCE-004.8 in the lymphatic nodes. Maisine CC is a long chain
lipid (C18:2) used to increase oral bioavailability and promote lymphatic
absorption (Caliph et al., 2000; Khoo et al., 2003). Autoimmune dis-
eases, including MS, are initiated in lymphoid tissues; furthermore, we
have also demonstrated that EHP-101 showed anti-inflammatory and
antifibrotic activities in a murine model of systemic sclerosis, another
autoimmune disease where the BBB is not affected (Garcia-Martin et al.,
2018). In addition, we show that EHP-101 alleviates neuroinflamma-
tion in CPZ-intoxicated mice. This model is considered independent of T
cells and B cells because RAG−/− mice show no difference in demye-
lination or remyelination (Arnett et al., 2001). CPZ-induced demyeli-
nating lesions are characterized by severe oligodendrocyte loss and
demyelination with concomitant activation of microglia and astrocytes,
but they do not induce BBB damage (Bakker and Ludwin, 1987; Kondo
et al., 1987; McMahon et al., 2002) and lack the characteristic T-cell
infiltration and consequently the peripheral autoimmune component of
the disease (Kipp et al., 2009).
Extensive experimental studies have revealed that activating HIF-1α
by inhibiting the activation of PHDs can provide neuroprotection and
perhaps remyelination mainly from the increased expression of HIF-1
target genes, which combat oxidative stress, improve blood oxygen and
glucose supply, promote glucose metabolism, regulate iron homeostasis
and block cell death signal pathways. Increasing HIF-1 activity may be
an important potential strategy to prevent the onset or to ameliorate the
pathogenesis of neurodegenerative diseases (Zhang et al., 2011). In
fact, activation of the HIF-1 pathway by hypoxia preconditioning pro-
cess induced by mild oxygen depletion is beneficial in a wide number of
neurological disorders, including MS (Esen et al., 2013; Stetler et al.,
2014). Interestingly, a recent report has shown that mild hypoxia
promotes recovery from preexisting inflammatory demyelinating dis-
ease and suggesting that this protection may be the result of enhanced
vascular integrity and accelerated apoptosis of infiltrated monocytes
(Halder and Milner, 2020). The cellular adaptation to severe or mild
hypoxia is very fast and involves the activation of the hypoxia-inducible
factor (HIF)-1α, whose activation may play a role in the inflammatory
Fig. 8. EHP-101 reduces axonal degeneration induced by CPZ. Representative
images of immunostaining of SMI-32+ cells in the corpus callosum of different
groups of animals (n = 5 animals per group). Axonal spheroids which are
characteristic of axonal pathology are identified with white arrows. Scale bar
equivalent to 20 μm.
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and the remitting phases of MS (reviewed by (Girolamo et al., 2014)).
Remarkably, the improvement of the myelination index was paralleled
by enhancement of oligodendrocyte progenitor cell (OPC) proliferation,
platelet-derived growth factor (PDGF)α-receptor expression, and pre-
cursor migration from the CC midline to the lateral parts followed by an
induction of the expression of myelin protein (Patel and Klein, 2011). In
addition, early astrogliosis in the demyelinated areas paralleled a
moderate stimulation of insulin-like growth factor (IGF)-1 expression
(Kipp et al., 2009). IGF-1 synergizes with fibroblast growth factor
(FGF)-2 to stimulate oligodendrocyte progenitor entry into the cell
cycle (Jiang et al., 2001). This is of particular interest because IGF-1
induced HIF-1 activation that could be mimicked by VCE-004.8 in the
brain, and PDGFα and FGF2 are also regulated by VCE-004.8-mediated
activation of the HIF pathway (Calvani et al., 2006; Navarrete et al.,
2018; Schito et al., 2012). Nevertheless, the mechanism of action of
EHP-101 in the remyelination process is still unknown. Although in our
transcriptomic analysis in the spinal cord of EAE mice we could not find
an upregulation of genes directly regulated by HIF-1α we cannot dis-
card that it could be related to the activation of this pathway by acting
on nearby tissues such as endothelial vascular cells. Further experi-
ments are required to confirm the involvement of HIF-1α in the efficacy
of EHP-101 on remyelination.
Demyelination and partial axonal damage in MS lesions are closely
associated with reactive activation of microglial cells which are seen in
close contact with axons, that reveal acute axonal injury, such as the
formation of axonal spheroids or a disturbance of fast axonal transport
(Ferguson et al., 1997; Trapp et al., 1998). Reactive microglia produce a
large array of toxic and proinflammatory molecules, which triggers
myelin destruction, oligodendrocyte deterioration, axon damage and
even neuronal loss (Popescu and Lucchinetti, 2012) (Song and Suk,
2017). Here we found that oral EHP-101 also prevented microglia ac-
tivation and demyelination in both spinal cord and brain, suggesting
that part of this effect could be mediated by the penetration of VCE-
004.8 in the brains of EAE mice. Moreover, we also found that EHP-101
preserves the axonal structure ameliorating the typical accumulation of
spheroids of SMI-32 used as a marker of axonal damage in CPZ in-
toxicated mice (Peterson et al., 2001; Trapp et al., 1998; Werner et al.,
2001). Again, this result suggests that VCE-004.8 can also cross the
BBB, which is not affected in the CPZ model (Bakker and Ludwin,
1987). However, we do not have direct measurement of the compound
in the brain of EAE and CPZ mice and further experiment are required
to validate this possibility.
Oligodendrocyte progenitor cells (OPCs) are produced from neu-
roepithelial stem cells and subsequently proliferate and migrate
throughout the entire spinal cord (Tsai et al., 2009). During differ-
entiation, oligodendrocytes initiate expression of myelin proteins cri-
tical for the achievement of proper functioning of the CNS (Louis et al.,
1992). Teneurin-4 (Tenm4) is a type II transmembrane protein that is
highly expressed in the CNS and whose expression is induced in re-
sponse to endoplasmic reticulum stress (Wang et al., 1998) and has
been suggested to be involved in bipolar disorder in humans
(Psychiatric, 2011). A mouse mutation, designated furue, which results
in tremors and severe hypomyelination of small-diameter axons, re-
duces oligodendrocyte differentiation especially in the spinal cord of
the CNS, and it has been associated with the absence of Tenm4 ex-
pression. Thus, Tenm4 is a critical regulator of oligodendrocyte dif-
ferentiation and CNS myelination (Suzuki et al., 2012). Herein we
showed for the first time that in EAE mice the expression of Tenm4 is
downregulated in the spinal cord and the treatment with EHP-101 re-
verses this downregulation probably as a result of the anti-in-
flammatory activity of VCE-004.8.
In addition, oligodendrocytes are electrically and metabolically
coupled through intercellular channels called gap junctions (GJs),
composed of connexins Cx29, Cx32 and Cx47 (Kleopa et al., 2004), with
other oligodendrocytes as well as with astrocytes. This glial network of
communication plays an important role in the homeostasis of brain
function (Giaume et al., 2010; Orthmann-Murphy et al., 2008). Several
studies have also provided the role of oligodendrocyte connexins in
acquired demyelinating CNS disorders, in particular MS and related
experimental models (Markoullis et al., 2012a; Markoullis et al.,
2012b). They also appear to have a regulatory role in neuroin-
flammation as their absence further aggravates inflammatory demye-
lination (Papaneophytou et al., 2018). Again, our results demonstrated
that EHP-101 prevented the downregulation of Gjc3 (connexin 29)
expression in EAE mice vs control mice. In light of the relevance of
Tenm4 and Gjc3 for oligodendrocyte function and myelin preservation,
our results further support the potential of EHP-101 to be developed as
a novel treatment of MS.
5. Conclusions
In conclusion, we have shown the protective effect of EHP-101
against demyelination and its capability to enhance remyelination.
These results open new strategies for the treatment of MS and other
demyelinating diseases, since novel therapies aimed at axonal re-
myelination are urgently needed.
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